Literature DB >> 21469660

20-Iodo-14,15-epoxyeicosa-8(Z)-enoyl-3-azidophenylsulfonamide: photoaffinity labeling of a 14,15-epoxyeicosatrienoic acid receptor.

Yuenmu Chen1, John R Falck, Vijaya L Manthati, Jawahar Lal Jat, William B Campbell.   

Abstract

Endothelium-derived epoxyeicosatrienoic acids (EETs) relax vascular smooth muscle by activating potassium channels and causing membrane hyperpolarization. Recent evidence suggests that EETs act via a membrane binding site or receptor. To further characterize this binding site or receptor, we synthesized 20-iodo-14,15-epoxyeicosa-8(Z)-enoyl-3-azidophenylsulfonamide (20-I-14,15-EE8ZE-APSA), an EET analogue with a photoactive azido group. 20-I-14,15-EE8ZE-APSA and 14,15-EET displaced 20-(125)I-14,15-epoxyeicosa-5(Z)-enoic acid binding to U937 cell membranes with K(i) values of 3.60 and 2.73 nM, respectively. The EET analogue relaxed preconstricted bovine coronary arteries with an ED(50) comparable to that of 14,15-EET. Using electrophoresis, 20-(125)I-14,15-EE8ZE-APSA labeled a single 47 kDa band in U937 cell membranes, smooth muscle and endothelial cells, and bovine coronary arteries. In U937 cell membranes, the 47 kDa radiolabeling was inhibited in a concentration-dependent manner by 8,9-EET, 11,12-EET, and 14,15-EET (IC(50) values of 444, 11.7, and 8.28 nM, respectively). The structurally unrelated EET ligands miconazole, MS-PPOH, and ketoconazole also inhibited the 47 kDa labeling. In contrast, radiolabeling was not inhibited by 8,9-dihydroxyeicosatrienoic acid, 5-oxoeicosatetraenoic acid, a biologically inactive thiirane analogue of 14,15-EET, the opioid antagonist naloxone, the thromboxane mimetic U46619, or the cannabinoid antagonist AM251. Radiolabeling was not detected in membranes from HEK293T cells expressing 79 orphan receptors. These studies indicate that vascular smooth muscle, endothelial cells, and U937 cell membranes contain a high-affinity EET binding protein that may represent an EET receptor. This EET photoaffinity labeling method with a high signal-to-noise ratio may lead to new insights into the expression and regulation of the EET receptor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21469660      PMCID: PMC3100183          DOI: 10.1021/bi102070w

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  53 in total

Review 1.  Epoxygenase pathways of arachidonic acid metabolism.

Authors:  D C Zeldin
Journal:  J Biol Chem       Date:  2001-07-12       Impact factor: 5.157

2.  Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release.

Authors:  D H Munzenmaier; D R Harder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-04       Impact factor: 4.733

3.  Evidence for a membrane site of action for 14,15-EET on expression of aromatase in vascular smooth muscle.

Authors:  Gary D Snyder; U Murali Krishna; J R Falck; Arthur A Spector
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

4.  Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis.

Authors:  J K Chen; J Capdevila; R C Harris
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

5.  The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells.

Authors:  I Fleming; B Fisslthaler; U R Michaelis; L Kiss; R Popp; R Busse
Journal:  Pflugers Arch       Date:  2001-07       Impact factor: 3.657

6.  14,15-Dihydroxyeicosatrienoic acid relaxes bovine coronary arteries by activation of K(Ca) channels.

Authors:  William B Campbell; Christine Deeter; Kathryn M Gauthier; Richard H Ingraham; J R Falck; Pin-Lan Li
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-05       Impact factor: 4.733

7.  14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries.

Authors:  Kathryn M Gauthier; Christina Deeter; U Murali Krishna; Y Krishna Reddy; Muralidhar Bondlela; J R Falck; William B Campbell
Journal:  Circ Res       Date:  2002-05-17       Impact factor: 17.367

8.  14,15-Epoxyeicosatrienoic acid induces vasorelaxation through the prostaglandin EP(2) receptors in rat mesenteric artery.

Authors:  Cui Yang; Yiu-Wa Kwan; Alice Lai-Shan Au; Christina Chui-Wa Poon; Qian Zhang; Shun-Wan Chan; Simon Ming-Yuen Lee; George Pak-Heng Leung
Journal:  Prostaglandins Other Lipid Mediat       Date:  2010-06-30       Impact factor: 3.072

9.  Binding of cytochrome P450 monooxygenase and lipoxygenase pathway products by heart fatty acid-binding protein.

Authors:  R L Widstrom; A W Norris; A A Spector
Journal:  Biochemistry       Date:  2001-01-30       Impact factor: 3.162

10.  The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands.

Authors:  L Ashley Cowart; Shouzuo Wei; Mei-Hui Hsu; Eric F Johnson; Murali U Krishna; John R Falck; Jorge H Capdevila
Journal:  J Biol Chem       Date:  2002-07-17       Impact factor: 5.157

View more
  27 in total

Review 1.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

2.  The biological actions of 11,12-epoxyeicosatrienoic acid in endothelial cells are specific to the R/S-enantiomer and require the G(s) protein.

Authors:  Yindi Ding; Timo Frömel; Rüdiger Popp; John R Falck; Wolf-Hagen Schunck; Ingrid Fleming
Journal:  J Pharmacol Exp Ther       Date:  2014-04-24       Impact factor: 4.030

Review 3.  Eicosanoids in metabolic syndrome.

Authors:  James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song
Journal:  Adv Pharmacol       Date:  2013

4.  Specific oxylipins enhance vertebrate hematopoiesis via the receptor GPR132.

Authors:  Jamie L Lahvic; Michelle Ammerman; Pulin Li; Megan C Blair; Emma R Stillman; Eva M Fast; Anne L Robertson; Constantina Christodoulou; Julie R Perlin; Song Yang; Nan Chiang; Paul C Norris; Madeleine L Daily; Shelby E Redfield; Iris T Chan; Mona Chatrizeh; Michael E Chase; Olivia Weis; Yi Zhou; Charles N Serhan; Leonard I Zon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-23       Impact factor: 11.205

5.  Functional screening for G protein-coupled receptor targets of 14,15-epoxyeicosatrienoic acid.

Authors:  Xuehong Liu; Zu-Yuan Qian; Fuchun Xie; Wei Fan; Jonathan W Nelson; Xiangshu Xiao; Sanjiv Kaul; Anthony P Barnes; Nabil J Alkayed
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-09-17       Impact factor: 3.072

6.  Role of CYP eicosanoids in the regulation of pharyngeal pumping and food uptake in Caenorhabditis elegans.

Authors:  Yiwen Zhou; John R Falck; Michael Rothe; Wolf-Hagen Schunck; Ralph Menzel
Journal:  J Lipid Res       Date:  2015-09-23       Impact factor: 5.922

Review 7.  Soluble epoxide hydrolase as a therapeutic target for obesity-induced disorders: roles of gut barrier function involved.

Authors:  Jianan Zhang; Maolin Tu; Zhenhua Liu; Guodong Zhang
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2020-09-19       Impact factor: 4.006

Review 8.  Endothelial control of vasodilation: integration of myoendothelial microdomain signalling and modulation by epoxyeicosatrienoic acids.

Authors:  David C Ellinsworth; Scott Earley; Timothy V Murphy; Shaun L Sandow
Journal:  Pflugers Arch       Date:  2013-06-08       Impact factor: 3.657

Review 9.  Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Authors:  Arthur A Spector; Hee-Yong Kim
Journal:  Biochim Biophys Acta       Date:  2014-08-02

10.  GPR40 is a low-affinity epoxyeicosatrienoic acid receptor in vascular cells.

Authors:  Sang-Kyu Park; Anja Herrnreiter; Sandra L Pfister; Kathryn M Gauthier; Benjamin A Falck; John R Falck; William B Campbell
Journal:  J Biol Chem       Date:  2018-05-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.